Top Markets
Coin of the day
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
株式のランク #17600
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
株価
$8.16
最終同期: 2025-06-26
時価総額
$234.57M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Regulus Therapeutics Inc. (RGLS)

カテゴリー

Regulus Therapeutics Inc.(RGLS)の配当利回りの履歴
Regulus Therapeutics Inc.(銘柄コード: RGLS)の配当利回り(TTM)は2023-12-31時点で0.00%です。
過去5年間の平均配当利回り: 0.00%
Regulus Therapeutics Inc.(RGLS)の2010から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
2013 0.00% 0.00%
2012 0.00% 0.00%
2011 0.00% 0.00%
2010 0.00% 0.00%
類似企業または競合他社の配当利回り(TTM)